Search Results
Oct 19, 2025, 08:45 ET SystImmune Announces iza-bren Meets One of the Dual Primary Endpoints in the BL-B01D1-303 Trial in Recurrent or Metastatic NPC Patients with Results Presented as a Late-Breaking Oral Presentation at ESMO
0.43; 95% CI 0.22 to 0.83). Furthermore, median progression-free survival (PFS) was 8.38 months with iza-bren compared to 4.34 months for chemotherapy (hazard ratio of 0.44; 95% confidence interval 0.32-0.62). The ORR and PFS benefits were consistent across all subgroup analysis. At the time of this
More news about: SystImmune, Inc.
Oct 18, 2025, 10:42 ET Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO
at the data cut-off date January 22, 2025, the median PFS was significantly longer in sac-TMT than in ICC (8.3 vs. 4.1 months; HR, 0.35; 95% CI, 0.26-0.48; P<0.0001). Clinical benefit was seen in sac-TMT independent of HER2 expression (HR for PFS in HER2-zero: 0.39, 95% CI, 0.26-0.57; in HER2-low: 0.31,
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Oct 18, 2025, 03:00 ET Florida Cancer Specialists & Research Institute Shaping the Future of Cancer Care at Global Congress
papillomavirus integration site mapping in advanced cervical cancer: The NRG Oncology/GOG-0240 NIH Cancer Moonshot.Second progression-free survival (PFS2) and subsequent treatment in patients (pts) with folate receptor alpha (FR⍺)-positive platinum-resistant ovarian cancer (PROC) treated with mirvetuximab
More news about: Florida Cancer Specialists & Research Institute
Oct 17, 2025, 10:00 ET Boehringer's HERNEXEOS® demonstrated a 77% objective response rate in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC
data cut-off, median values for duration of response (DoR) and progression-free survival (PFS) were not yet mature, with 47% of patients remaining on treatment and encouraging 6-month rates for DoR of 80% and PFS of 79%. Data presented at ESMO demonstrated a manageable safety profile
More news about: Boehringer Ingelheim
Oct 17, 2025, 10:00 ET SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025
endpoints include objective response rate (ORR) by RECIST 1.1 criteria, duration of response (DoR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OR) and PK analysis. About EGFRmt NSCLC
More news about: SystImmune, Inc.
Oct 17, 2025, 05:42 ET Kelun-Biotech's Core product Trastuzumab Botidotin Approved for Marketing by NMPA for HER2-positive BC
botidotin monotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS) as assessed by the blinded independent central review (BICR) compared with T-DM1; the beneficial trend for overall survival (OS) of trastuzumab botidotin
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Oct 16, 2025, 11:44 ET KENTRO PARTNERS WITH THE PFS TEAM ON THE VA INTEGRATED HEALTHCARE TRANSFORMATION 2.0 CONTRACT
MCLEAN, Va., Oct. 16, 2025 /PRNewswire/ -- Kentro is proud to partner with Prometheus Federal Services (PFS) on the Department of Veterans Affairs (VA) Integrated Healthcare Transformation 2.0 (IHT 2.0) contract. The 10-year, $14 billion multiple-award IDIQ
More news about: Kentro
Oct 16, 2025, 08:00 ET TECVAYLI® plus DARZALEX FASPRO® combination regimen significantly improves progression-free survival and overall survival versus standard of care
First Phase 3 study (MajesTEC-3) of an investigational combination to show benefit in PFS and OS in relapsed/refractory multiple myeloma as early as second line
More news about: Johnson & Johnson
Oct 14, 2025, 17:31 ET Anaplastic Astrocytoma Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2025-2034) | DelveInsight
2024, reported that the STELLAR Phase III trial demonstrated a clinically meaningful improvement in Overall Survival (OS) and Progression-Free Survival (PFS) for patients with Grade 3 IDH-mutant astrocytoma who had progressed after radiation and adjuvant temozolomide, compared to lomustine alone. Since that
More news about: DelveInsight Business Research, LLP
Oct 14, 2025, 09:00 ET Lunit AI Predicts Immunotherapy Outcome in Colorectal, Kidney, and Lung Cancer at ESMO 2025
progression-free survival (PFS) and overall survival (OS) compared to biomarker-low patients, while no such benefit was observed in the control arm. Validation in the AVETRIC cohort confirmed improved survival outcomes for biomarker-high patients receiving ICI-based therapy, with better PFS and OS compared to
More news about: Lunit
Oct 14, 2025, 07:00 ET Mayfair Gold Files Technical Report for Fenn-Gib Gold Project
include, but are not limited to, statements regarding the design, development and execution of the Fenn-Gib Gold Project, the timing for completion of the PFS, the advancement of the Fenn-Gib Gold Project to operation and the timing thereof, the advancing of environmental approvals, permits and project designs, mitigate
More news about: Mayfair Gold Corp.
Oct 13, 2025, 12:10 ET Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Southwestern Harold C. Simmons Comprehensive Cancer Center) reported a median progression-free survival (PFS) of 32.3 months. This reflects a notable 12.3-month improvement over the 20.0-month median PFS observed with osimertinib monotherapy, as reported by Watanabe et al. in a real-world clinical setting.
More news about: Actinium Pharmaceuticals, Inc.
Oct 13, 2025, 07:30 ET ADC Therapeutics Announces $60 Million Private Placement
consistent with or different from the LOTIS-7 data presented at EHA and ICML and future compendia and regulatory strategy and opportunity; the timing of the PFS events for LOTIS-5 and the results of the trial and full FDA approval; the Company's ability to grow ZYNLONTA® revenue in the United States
More news about: ADC Therapeutics SA
Oct 13, 2025, 07:15 ET AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors
SOC. All patients in this group had received the platinum-based SOC treatment as first-line therapy (1L SOC). Progression-free survival (PFS) during 1L SOC and PFS with ABBV-706 monotherapy as a subsequent line of treatment were analyzed in the same patients by paired Kaplan-Meier analysis. The findings
More news about: AbbVie
Oct 12, 2025, 18:27 ET Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR mutations and Active Brain Metastases at the ESMO Congress 2025
ORR and confirmed per investigator-assessed Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and the secondary endpoints include DOR, DCR, PFS, OS, intracranial efficacy by RANO-BM criteria, PK and safety. About Zipalertinib
More news about: Taiho Oncology
Oct 08, 2025, 09:00 ET Vistina, a Subsidiary of Hoplon Capital, and HPS Investment Partners Announce Collaboration to Expand Asset-Based Financing Origination to Borrowers
investment-grade asset-based financing solutions to corporate borrowers," said Scott Kapnick, Chairman of the Blackrock Private Financing Solutions (PFS) Executive Office and Chief Executive Officer of HPS. "This engagement reflects HPS's focus on utilizing its ability to provide borrowers with bespoke
More news about: Hoplon Capital
Oct 07, 2025, 20:15 ET CARsgen Presents Results on GPRC5D CAR-T CT071 in The Lancet Haematology
including all 10 with CR or sCR. Median time to MRD negativity was 29 days (IQR 29-29). Median duration of response (DoR), progression-free survival (PFS) and overall survival (OS) were not reached. The data cutoff for all analyses was December 9, 2024. About
More news about: CARsgen Therapeutics
Oct 07, 2025, 08:00 ET ARIS MINING DELIVERS 25% PRODUCTION GROWTH IN Q3 2025
Marmato Complex, expected to start ramping up production in H2 2026. In addition, Aris Mining operates the 51% owned Soto Norte joint venture, where a PFS study is complete on a new, smaller scale development plan which confirms Soto Norte as a high-quality, long-life project with robust economics and industry-leading
More news about: Aris Mining Corporation
Oct 06, 2025, 23:00 ET DEFENSE METALS PROVIDES BUSINESS UPDATE
Following the release of the Pre-Feasibility Study ("PFS") for the Wicheeda project in May 2025 (see company NR dated April 7, 2025), the Company has been working towards commencing a Definitive Feasibility Study ("DFS") in the first half of 2026. The PFS, prepared in compliance with National Instrument
More news about: Defense Metals Corp.
Oct 06, 2025, 06:30 ET Thesis Gold Drills 89.3 Metres of 1.10 Grams per Tonne Gold to Extend Mineralization at the Bingo Zone
exists within this established economic framework. Updated project economics are expected in Q4 2025 with the results of a Prefeasibility Study (the 2025 PFS) led by Ausenco Engineering Canada ULC. Highlights
More news about: Thesis Gold Inc.
Oct 02, 2025, 18:37 ET FDA Approves Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
offers a new way to manage this aggressive disease and gives patients and their physicians a new treatment option with the potential to increase both PFS and OS. We're proud to advance the standard of care for ES-SCLC and we continue to pursue opportunities in cancer research that improve lives."
More news about: Jazz Pharmaceuticals plc
Oct 01, 2025, 16:05 ET ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
consistent with or different from the LOTIS-7 data presented at EHA and ICML and future regulatory and compendia strategy and opportunity; the timing of the PFS events for LOTIS-5 and the results of the trial and full FDA approval for ZYNLONTA®; future safety and efficacy results of the Phase 2 IIT in MZL and
More news about: ADC Therapeutics SA
Oct 01, 2025, 07:30 ET Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars
Bosaya™ 60 mg/mL injection in a single-dose prefilled syringe (PFS) and Aukelso™ 120 mg/1.7 mL (70 mg/mL injection for subcutaneous use in a single-dose vial, are biosimilars to Amgen's Prolia® and Xgeva®, respectively.
More news about: Biocon Biologics
Sep 29, 2025, 14:37 ET ARIS MINING COMPLETES SALE OF JUBY GOLD PROJECT
Marmato Complex, expected to start ramping up production in H2 2026. In addition, Aris Mining operates the 51% owned Soto Norte joint venture, where a PFS study is complete on a new, smaller scale development plan which confirms Soto Norte as a high-quality, long-life project with robust economics and industry-leading
More news about: Aris Mining Corporation
Sep 29, 2025, 07:00 ET Blue Sky Uranium Launches Exploration Program after Completing Ivana Deposit Infill Drilling Program and Advances towards Prefeasibility Study at Amarillo Grande Project, Argentina
completed the previously announced infill drilling program at the Ivana Deposit, marking a key milestone towards completing a prefeasibility study ("PFS"). The infill program included 4,959 metres of drilling across 328 holes, bringing the total drilling at the deposit to 15,839 metres of drilling
More news about: Blue Sky Uranium Corp.